-
1
-
-
84858055719
-
Initial experience with dabigatran etexilate at Auckland City Hospital
-
Feb 10
-
Bell S, Nand J, Spriggs D, Young L, Dawes M. Initial experience with dabigatran etexilate at Auckland City Hospital. N Z Med J. 2012 Feb 10;125(1349):105-7. http://journal.nzma.org.nz/journal/125-1349/5064/
-
(2012)
N Z Med J
, vol.125
, Issue.1349
, pp. 105-107
-
-
Bell, S.1
Nand, J.2
Spriggs, D.3
Young, L.4
Dawes, M.5
-
2
-
-
70349306707
-
RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation
-
Sep 17
-
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. http://www.nejm.org/doi/full/10.1056/NEJMoa0905561
-
(2009)
N Engl J Med
, vol.361
, Issue.12
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
Eikelboom, J.4
Oldgren, J.5
-
3
-
-
78049490509
-
-
Erratum in, Nov 4
-
Erratum in: N Engl J Med. 2010 Nov 4;363(19):1875-6. http://www.nejm.org/doi/full/10.1056/NEJMc1007378
-
(2010)
N Engl J Med
, vol.363
, Issue.19
, pp. 1875-1876
-
-
-
4
-
-
84857804517
-
-
Boehringer Ingelheim. Dabigatran etexilate, August, Table 7.3.1:8
-
Boehringer Ingelheim. Dabigatran etexilate. Advisory committee briefing document submitted to the Food and Drug Administration, August 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf Table 7.3.1:8.
-
(2010)
Advisory Committee Briefing Document Submitted to The Food and Drug Administration
-
-
-
6
-
-
84863517767
-
The use of antithrombotic medicines in general practice: A consensus statement
-
The use of antithrombotic medicines in general practice: a consensus statement. Best Practice Journal 2011;38:10-27. http://www.bpac.org.nz/magazine/2011/october/antithrombotic.asp
-
(2011)
Best Practice Journal
, vol.38
, pp. 10-27
-
-
-
7
-
-
79958126202
-
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RELY) trial
-
May 31
-
Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RELY) trial. Circulation. 2011 May 31;123(21):2363-72. http://circ.ahajournals.org/content/123/21/2363.long
-
(2011)
Circulation
, vol.123
, Issue.21
, pp. 2363-2372
-
-
Eikelboom, J.W.1
Wallentin, L.2
Connolly, S.J.3
Ezekowitz, M.4
Healey, J.S.5
-
8
-
-
84857853180
-
Bleeding risk with dabigatran in the frail elderly
-
Mar 1
-
Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012 Mar 1;366:864-6. http://www.nejm.org/doi/full/10.1056/NEJMc1112874
-
(2012)
N Engl J Med
, vol.366
, pp. 864-866
-
-
Harper, P.1
Young, L.2
Merriman, E.3
-
9
-
-
84859032048
-
Updated data sheet for dabigatran etexilate
-
Updated data sheet for dabigatran etexilate. Best Practice Journal 2011;41:50-51. http://www.bpac.org.nz/magazine/2011/december/dabigatran.asp
-
(2011)
Best Practice Journal
, vol.41
, pp. 50-51
-
-
|